ArticlePloS one2023

A trial-based cost-utility analysis of sugemalimab vs. placebo as consolidation therapy for unresectable stage III NSCLC in China.

Wei Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.